Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 2/20 | 0.57 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.57 |
| ▸ | TERT | O14746 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212527 | 0.82 | PABPC1 (0.64) | PABPC1FTOCHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL3974443 | 0.81 | PABPC1 (0.62) | PABPC1FTOCHRM2HTR1AADRA2A | |
| SCHEMBL9623457 | 0.79 | PABPC1 (0.50) | PABPC1FTOTERTCHRM2HTR1A | |
| Acetic Acid SCHEMBL25299219 | 0.77 | PABPC1 (0.58) | PABPC1FTOMEN1ALDH1A1KMT2A | |
| Acetic Acid SCHEMBL30498942 | 0.77 | PABPC1 (0.58) | PABPC1FTOMEN1ALDH1A1KMT2A | |
| SCHEMBL7712243 | 0.76 | FTO (0.81) | PABPC1FTOTERTCHRM2HTR1A | |
| SCHEMBL3746619 | 0.74 | PABPC1 (0.51) | PABPC1FTOTERTCHRM2HTR1A | |
| Mitonafide SCHEMBL62046 | 0.73 | FTO (1.00) | PABPC1FTOMEN1ALDH1A1LMNA | |
| Mitonafide SCHEMBL29352711 | 0.73 | FTO (1.00) | PABPC1FTOMEN1ALDH1A1LMNA | |
| Mitonafide SCHEMBL29499462 | 0.73 | FTO (1.00) | PABPC1FTOMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878984-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2018-01-30 | — | — | US | disclosed |
| US-20140378503-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY | 2014-12-25 | — | — | US | disclosed |
| US-8829025-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130225634-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2013-08-29 | — | — | US | disclosed |
| US-8420665-B2 | Anti-cancer compounds | NORTHWESTERN UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100303719-A1 | ANTI-CANCER COMPOUNDS | NORTHWESTERN UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378503-A1 | ANTI-CANCER COMPOUNDS | TP53, MKI67, MYC | PABPC1 1306/4885FTO 4344/4885TERT 2451/4885 |
| US-20100303719-A1 | ANTI-CANCER COMPOUNDS | TP53, MKI67, MYC | PABPC1 1306/4885FTO 4344/4885TERT 2451/4885 |
| US-20130225634-A1 | ANTI-CANCER COMPOUNDS | TP53, MKI67, MYC | PABPC1 1306/4885FTO 4344/4885TERT 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.